Table 2.
Univariate analysis and multivariate analysis of the prognostic factors on OS in patients with total SCLC
Factors | Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|---|
|
|
||||||
MST (m) | 2-y OS (%) | 3-y OS (%) | P | HR | 95% CI | P | |
Gender | |||||||
Male | 17 | 33.5 | 19.1 | ||||
Female | 22 | 46.2 | 38.8 | 0.077 | |||
Age (years) | |||||||
65-70 | 19.7 | 43.0 | 25.9 | 0.296 | |||
≥ 70 | 17.0 | 31.4 | 22.3 | ||||
KPS | |||||||
≥ 80 | 17.2 | 40.1 | 25.2 | ||||
< 80 | 17.3 | 34.6 | 20.0 | 0.092 | |||
Wight loss | |||||||
< 5% | 17.7 | 37.1 | 22.7 | ||||
≥ 5% | 13.0 | 28.1 | 19.0 | 0.166 | |||
Smoking | |||||||
Yes | 17.0 | 37.5 | 22.9 | ||||
No | 17.9 | 33.7 | 20.5 | 0.888 | |||
Cycle of ChT | |||||||
< 4 | 11.0 | 13.5 | 4.5 | 0.301- | |||
≥ 4 | 20.7 | 45.1 | 29.2 | < 0.001 | 0.486 | 0.786 | 0.003 |
Pleural effuion | |||||||
Yes | 14.0 | 30.0 | 12.3 | ||||
No | 17.9 | 37.7 | 23.8 | 0.251 | |||
Disease extent | |||||||
LS | 22.0 | 45.0 | 30.5 | 2.022- | |||
ES | 13.4 | 26.5 | 13.7 | < 0.001 | 3.034 | 4.552 | < 0.001 |
Obstructive | |||||||
Pneuontise | |||||||
Yes | 14.0 | 32.2 | 20.1 | ||||
No | 19.0 | 39.6 | 24.6 | 0.082 | |||
NSE (ng/mL) | |||||||
≥ 17 | 17.0 | 32.1 | 18.9 | 0.642- | |||
< 17 | 26.0 | 50.4 | 34.4 | 0.003 | 1.111 | 1.924 | 0.706 |
CEA (ng/mL) | |||||||
≥ 3.4 | 17.0 | 33.5 | 22.4 | ||||
< 3.4 | 17.4 | 42.8 | 23.9 | 0.552 |
OS, overall survival; SCLC, small cell lung cancer; KPS, Karnofsky performance status; ChT, chemotherapy; LS, limited-stage; ES, extensive-stage; NSE, neuron-specific enolase; CEA, carcinoembryonic antigen.